Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema

1. november 2026 opdateret af: Abdullah Goktug Yazar, Kayseri City Hospital

Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control

This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

40

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Kayseri, Tyrkiet (Türkiye), 38080
        • Kayseri City Training and Research Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
  • Diagnosis supported by lymphoscintigraphy
  • Indication for intensive-phase complex decongestive therapy
  • No previous full course of complex decongestive therapy on the affected limb
  • Written informed consent

Exclusion Criteria:

  • Active cellulitis or erysipelas at the measurement sites
  • Active, recurrent, or metastatic malignancy
  • Decompensated heart failure or history of deep vein thrombosis
  • Bilateral lymphedema
  • Cognitive impairment preventing adherence to treatment

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Lower-limb lymphedema, complex decongestive therapy

Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control.

Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.

Andre navne:
  • Complete Decongestive Therapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Tidsramme: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)

Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique.

Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Tidsramme: Baseline and end of week 4

Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique).

Baseline and end of week 4
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Tidsramme: Baseline and end of week 4

Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography.

Baseline and end of week 4
Change in subcutaneous tissue thickness of the unaffected (control) limb
Tidsramme: Baseline and end of week 4

Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control.

Baseline and end of week 4
Change in body weight
Tidsramme: Baseline and end of week 4

Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change.

Baseline and end of week 4

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Tidsramme: Baseline and end of week 4

Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2).

Baseline and end of week 4

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Abdullah Goktug Yazar, MD, Kayseri City Hospital
  • Studiestol: Ayse Guc, MD, Kayseri City Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2025

Primær færdiggørelse (Faktiske)

1. januar 2026

Studieafslutning (Faktiske)

1. januar 2026

Datoer for studieregistrering

Først indsendt

1. november 2026

Først indsendt, der opfyldte QC-kriterier

1. november 2026

Først opslået (Faktiske)

5. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2025-491
  • 491 (Anden identifikator: Kayseri City Hospital Clinical Research Ethics Committee)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner